IL324785A - Modified immunoglobulin variable heavy domains having reduced immunogenicity - Google Patents

Modified immunoglobulin variable heavy domains having reduced immunogenicity

Info

Publication number
IL324785A
IL324785A IL324785A IL32478525A IL324785A IL 324785 A IL324785 A IL 324785A IL 324785 A IL324785 A IL 324785A IL 32478525 A IL32478525 A IL 32478525A IL 324785 A IL324785 A IL 324785A
Authority
IL
Israel
Prior art keywords
polypeptide
amino acid
cytokine receptor
group
seq
Prior art date
Application number
IL324785A
Other languages
English (en)
Hebrew (he)
Inventor
Patrick L Lupardus
Deepti Rokkam
Michael Totagrande
Original Assignee
Synthekine Inc
Patrick L Lupardus
Deepti Rokkam
Michael Totagrande
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthekine Inc, Patrick L Lupardus, Deepti Rokkam, Michael Totagrande filed Critical Synthekine Inc
Publication of IL324785A publication Critical patent/IL324785A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL324785A 2023-06-07 2024-06-07 Modified immunoglobulin variable heavy domains having reduced immunogenicity IL324785A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363506797P 2023-06-07 2023-06-07
PCT/US2024/033155 WO2024254562A2 (fr) 2023-06-07 2024-06-07 Domaines lourds variables d'immunoglobuline modifiés ayant une immunogénicité réduite

Publications (1)

Publication Number Publication Date
IL324785A true IL324785A (en) 2026-01-01

Family

ID=93796476

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324785A IL324785A (en) 2023-06-07 2024-06-07 Modified immunoglobulin variable heavy domains having reduced immunogenicity

Country Status (8)

Country Link
EP (1) EP4724499A2 (fr)
JP (1) JP2026521433A (fr)
KR (1) KR20260021032A (fr)
CN (1) CN121941708A (fr)
AU (1) AU2024285577A1 (fr)
IL (1) IL324785A (fr)
MX (1) MX2025014711A (fr)
WO (1) WO2024254562A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190112380A1 (en) * 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
WO2022040586A2 (fr) * 2020-08-21 2022-02-24 Novartis Ag Compositions et méthodes pour la génération in vivo de cellules exprimant car
BR112023005152A2 (pt) * 2020-09-21 2023-04-25 Systimmune Inc Anticorpo biespecífico com especificidade intensificada (seba)
CN115703829B (zh) * 2021-08-16 2025-01-10 厦门大学 针对SARS-CoV-2的单域抗体及其用途

Also Published As

Publication number Publication date
WO2024254562A2 (fr) 2024-12-12
JP2026521433A (ja) 2026-06-30
KR20260021032A (ko) 2026-02-12
CN121941708A (zh) 2026-04-28
MX2025014711A (es) 2026-06-01
WO2024254562A3 (fr) 2025-03-20
AU2024285577A1 (en) 2025-12-04
EP4724499A2 (fr) 2026-04-15

Similar Documents

Publication Publication Date Title
US9035029B2 (en) CX3CR1-binding polypeptides comprising immunoglobulin single variable domains
JP2020018298A (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
WO2020038397A1 (fr) Anticorps bispécifiques anti-pd-l1/anti-lag3 et leurs utilisations
US20150010539A1 (en) Anti-cd25 antibodies and their uses
US20150010538A1 (en) Anti-cd25 antibodies and their uses
US20240076392A1 (en) Anti-cd123 binding molecules and uses thereof
CN118638234B (zh) 抗bdca2抗体及其制备方法和应用
TW202311295A (zh) 一種抗原結合分子
WO2022156739A1 (fr) Molécule de liaison à l'antigène se liant spécifiquement à bcma et cd3 et son utilisation médicale
KR20250046283A (ko) Gucy2c 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이의 의약적 용도
AU2024285577A1 (en) Modified immunoglobulin variable heavy domains having reduced immunogenicity
WO2026103784A1 (fr) Anticorps à domaine unique anti-cd3 et leurs utilisations
WO2025077834A1 (fr) Anticorps anti-il-4 ra et leurs utilisations
WO2025026282A1 (fr) Anticorps multispécifiques de type e modifiés
WO2025185656A1 (fr) Anticorps bispécifique anti-pd-l1 et cd40 et son utilisation
JP2025532504A (ja) 抗ｉｌｔ４抗体及びその医薬的使用
JP2025528101A (ja) 多重特異性ポリペプチド複合体
HK1214277A1 (zh) 生产异源多聚体蛋白质